A 5-year research project starting in June 2011 will investigate the long-term effects of resveratrol in humans. Dr. Steen Bønløkke Pedersen from Aarhus University will lead the research using Fluxome® Resveratrol as the active ingredient.
The Danish Council for Strategic Research has granted DKK 19.5 mil (USD 3.4 mil) for a research project for long investigation of resveratrol on management of metabolic syndrome, osteoporosis and inflammation in humans. The project participants are Aarhus University, Aarhus University Hospital, University of Southern Denmark, Roskilde University, Pennsylvania State University, and Fluxome A/S who will be supplying Fluxome® Resveratrol for the trials.
Dr. Steen Bønløkke Pedersen from Aarhus University will be leading the 5-year research project with 6 PhD students attached. The project starts in June 2011 by looking at the long-term effect of resveratrol on human subjects; the participants will consume Fluxome® Resveratrol for a period of 12 months. The objective of the project is to prove that resveratrol in humans can neutralize the detrimental effect of obesity on the whole body metabolism such as low-grade chronic inflammation, insulin resistance, and lipid infiltration/inflammation in liver and skeletal muscle.
Low-grade inflammation is associated with type 2 diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and osteoporosis. Resveratrol has strong anti-inflammatory effects and is a promising compound with the potential neutralizes obesity-induced diseases and osteoporosis. The new project focuses on the effect of resveratrol on insulin sensitivity, inflammation, bone and fatty liver disease in a long-term study in humans. Pre-clinical trials have demonstrated that one effect of resveratrol is reduction of inflammation and the same effect is expected to be seen in humans.